Sherbrooke Park Advisers LLC Makes New Investment in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sherbrooke Park Advisers LLC acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,786 shares of the biotechnology company’s stock, valued at approximately $200,000.

Other large investors also recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC increased its position in Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Arcturus Therapeutics in the fourth quarter valued at approximately $71,000. National Bank of Canada FI lifted its stake in Arcturus Therapeutics by 639.6% in the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock worth $94,000 after acquiring an additional 4,784 shares during the last quarter. Kennedy Capital Management LLC lifted its stake in Arcturus Therapeutics by 22.7% in the fourth quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 2,036 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 3,705 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ARCT has been the subject of several recent analyst reports. Citigroup restated a “buy” rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. Canaccord Genuity Group cut their target price on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. Wells Fargo & Company dropped their price objective on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of “Buy” and a consensus price target of $57.80.

Arcturus Therapeutics Price Performance

Shares of ARCT stock opened at $12.70 on Wednesday. The firm has a market cap of $344.44 million, a P/E ratio of -5.72 and a beta of 2.36. Arcturus Therapeutics Holdings Inc. has a 1-year low of $8.04 and a 1-year high of $45.00. The firm’s 50-day simple moving average is $11.47 and its 200-day simple moving average is $15.12.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The business had revenue of $29.38 million during the quarter, compared to the consensus estimate of $25.64 million. Analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.